Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research.
Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research.
复制标题
DOI：
10.1007/s11904-008-0027-z
复制
发表时间：
2008-11-01
影响因子：
4.6
通讯作者：
Gordon, Christopher M
中科院分区：
文献类型：
--
作者：
Stirratt, Michael J;Gordon, Christopher M
预防艾滋病毒的生物医学方法(如杀微生物剂、抗逆转录病毒暴露前预防)正在进行临床试验，以测试其有效性。从完成的试验中出现的一个关键考虑因素是坚持研究产品的关键作用。不理想的产品依从性可能会危及临床试验结果，并最终破坏生物医学预防方法在未来任何实际应用中的有效性。加强生物医学艾滋病毒预防产品坚持的努力可以受益于为坚持艾滋病毒治疗而开发的现有研究方法、发现和干预措施。对治疗依从性的研究与基于药物的生物医学预防策略最相关，例如针对单纯疱疹病毒-2的抗逆转录病毒暴露前预防和阿昔洛韦。艾滋病毒治疗依从性文献可以为此类生物医学预防策略的研究提供三个方面的信息：1)评估药物依从性的专门方法，2)强调社会背景作为依从性决定因素的研究结果，以及3)承诺改善依从性的行为干预。
Biomedical approaches to HIV prevention (eg, microbicides, antiretroviral preexposure prophylaxis) are undergoing clinical trials to test their efficacy. One key consideration emerging from completed trials is the critical role of adherence to the investigational product. Suboptimal product adherence may compromise clinical trial results and ultimately undermine the effectiveness of biomedical prevention methods in any future real-world use. Efforts to strengthen biomedical HIV prevention product adherence can benefit from existing research methodologies, findings, and interventions developed for adherence to HIV treatment. Research on treatment adherence is most relevant to medication-based biomedical prevention strategies, such as antiretroviral preexposure prophylaxis and acyclovir for herpes simplex virus-2. Three areas where HIV treatment adherence literature can inform research on such biomedical prevention strategies are 1) specialized methods for assessing medication adherence, 2) research findings emphasizing social context as an adherence determinant, and 3) promising behavioral interventions to improve adherence.